Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

GlobeNewsWire • Dec 12, 2025

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Added 458,295 shares of Cytokinetics, a $25,187,893 net position change Transaction represents a 13.8% position relative to 13F reportable assets under management Post-trade stake: 458,295 shares valued at $25,187,893 CYTK is now the fund's 2nd-largest holding by reported U.S. equity positions These 10 Stocks Could Mint the Next Wave of Millionaires ›

The Motley Fool • Dec 8, 2025

Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report?

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 5, 2025

3 Potential Mid-Cap Biotech Buyout Targets In 2026

The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday.  The sector has bounced back since. However, small biotech stocks have been on a huge run since mid-September, due primarily to a notable uptick in M&A activity across the industry. Numerous small and midcap biotech/biopharma stocks have been purchased for significant buyout premiums in recent months.

Seeking Alpha • Dec 3, 2025

Cytokinetics: A Heavily Mispriced Cardiovascular Platform

Cytokinetics is positioned as a precision cardiac mechanics platform leader, with aficamten as the first proof-of-concept and multiple pipeline assets. Aficamten's differentiated REMS, rapid titration, and superior safety could disrupt the cardiac myosin inhibitor market, expanding prescriber adoption and accelerating patient switching from competitors. CYTK's robust cash position, efficient commercial model, and underappreciated pipeline support a sum-of-the-parts valuation of $90–$158 per share, far above current levels.

Seeking Alpha • Nov 19, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to Jeffrey Hessekiel, the Company's Executive Vice President, Chief Legal and Administrative Officer, whose employment commenced on November 14, 2025, as a material inducement to his employment.

GlobeNewsWire • Nov 18, 2025

CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 17, 2025.

GlobeNewsWire • Nov 17, 2025

Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Incorporated Investors

LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Incorporated, (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion.

GlobeNewsWire • Nov 17, 2025

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders

NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

PRNewsWire • Nov 17, 2025

CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline. So what: If you purchased Cytokinetics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

PRNewsWire • Nov 18, 2025